The prevalence and severity of allergies and asthma in particular are increasing worldwide. Currently, asthma is considered a chronic inflammatory pulmonary syndrome in its classic form is associated with the uncontrolled T helper cell 2 (Th2) activities . Murine models have been developed to study the mechanisms of asthma and ovalbumin (OVA) is the most commonly used allergen. In previous work with the OVA model, we show that activation of the immune system by agonists of Toll-like receptors (TLRs) is a potent immune mechanism to reduce allergic reactions. Based on these studies, we postulate that the agonist of TLR 9, CpG containing oligodeoxynucleotides (CPG) may reduce allergic responses directly or indirectly inhibiting the activity of Th2 cells and their action can be enhanced with aggregation to a reagent of liposomal transfection N- [1- (2,3-Dioleoyloxy) propyl] -N, N-methyl N-trimethylammonium sulfate (DOTAP).This project aims to delineate therapeutic applications of CPG using DOTAP in an experimental model of ovalbumin -induced astma and their cellular and molecular mechanisms.
News published in Agência FAPESP Newsletter about the scholarship: